不止“銷毀”蛋白：這類新型藥物正在改寫分子間的“合作”規則

編者按：誘導接近（induced proximity）機制正在為新藥開發提供一種不同于傳統“占據靶點、抑制活性”的思路：通過藥物將靶蛋白、E3連接酶、伴侶蛋白、抗體、受體或其他細胞效應系統拉近，重新塑造分子之間的空間關系，從而改變疾病相關靶點的功能或命運。2026年第二季度，誘導接近領域的最新進展呈現出以下趨勢：

第一，首款蛋白降解靶向嵌合體獲批，分子膠降解劑取得后期臨床積極結果，顯示靶向蛋白降解劑已經走向監管驗證，并正從癌癥向免疫炎癥等更廣泛疾病領域延伸。第二，RAS分子膠抑制劑和抗體偶聯降解劑（DAC）等進展表明，誘導接近不再局限于“降解蛋白”，而是正在拓展為一種更廣義的新藥設計模式。第三，大藥企合作和資本投入持續活躍，產業界對誘導接近藥物的關注正在從經典蛋白降解劑擴展到更豐富的誘導接近技術平臺和復雜分子形式。

面對這類藥物在三元復合體形成、靶點選擇性、遞送、體內暴露、藥效轉化和CMC開發等方面的挑戰，藥明康德依托一體化、端到端的CRDMO賦能平臺，構建了覆蓋蛋白降解靶向嵌合體、分子膠、調節誘導接近靶向嵌合體、抗體偶聯降解劑等多種分子類型的能力體系，為全球合作伙伴提供從早期發現、篩選、合成、分析純化、測試到DMPK、生物分析和后續開發生產的系統支持，助力更多誘導接近藥物加速走向臨床、惠及患者。

首款蛋白降解靶向嵌合體獲批，蛋白降解劑不再局限于癌癥

2026年第二季度，誘導接近藥物領域迎來重要里程碑。由輝瑞（Pfizer）和Arvinas聯合開發的Veppanu（vepdegestrant）獲得，用于治療攜帶ESR1突變、ER陽性/HER2陰性晚期或轉移性乳腺癌成人患者。這項批準的意義不只在于一款乳腺癌新藥進入臨床應用，更在于它證明了通過誘導靶蛋白與E3連接酶接近、進而實現靶向蛋白降解的藥物設計理念，已經能夠轉化為監管機構認可的上市藥品。

與此同時，分子膠類蛋白降解劑也在血液腫瘤領域繼續獲得積極臨床結果。百時美施貴寶（Bristol Myers Squibb）在2026年美國臨床腫瘤學會（ASCO）年會上公布了CELMoD藥物mezigdomide聯合carfilzomib和dexamethasone治療復發或難治性多發性骨髓瘤的3期SUCCESSOR-2研究結果。與carfilzomib和dexamethasone對照方案相比，mezigdomide聯合方案將疾病進展或死亡風險降低52%，中位無進展生存期（PFS）分別為18.0個月和8.3個月。該公司的另一款CELMoD藥物iberdomide正在接受美國FDA審評，有望成為首個獲批的CELMoD類藥物。

值得一提的是，蛋白降解劑的應用范圍已經不局限于實體瘤和血液腫瘤。Kymera Therapeutics在4月宣布，美國FDA授予其口服STAT6降解劑KT-621快速通道資格，用于治療中重度嗜酸性粒細胞性哮喘。KT-621正在中重度嗜酸性粒細胞性哮喘和中重度特應性皮炎中開展2b期研究。

該公司與賽諾菲（Sanofi）聯合開發的IRAK4靶向蛋白降解劑KT-485（SAR447971）正在1期臨床試驗中接受評估，用于治療化膿性汗腺炎（HS）患者。Nurix Therapeutics的布魯頓氏酪氨酸激酶（BTK）靶向蛋白降解劑bexobrutideg不僅在治療慢性淋巴細胞白血病（CLL）的1期臨床試驗中達到83%的客觀緩解率（ORR），也在早期臨床研究中也顯著降低皮膚中的BTK水平，支持其在慢性自發性蕁麻疹等炎癥和免疫疾病中的進一步探索。

這些進展共同說明，抗癌蛋白降解劑已經在后期臨床開發和監管批準方面達到重要里程碑；在癌癥之外，蛋白降解劑也有望進入免疫和炎癥疾病、神經系統疾病等更廣泛領域。對于轉錄因子、支架蛋白、耐藥突變蛋白或具有非酶活性功能的靶點而言，“降解”可能比“抑制”提供更全面的功能調控方式。

RAS分子膠崛起，誘導接近不再局限于蛋白降解

然而，誘導接近并不止于“讓致病蛋白被降解”。近年來進展迅速的RAS三元復合體抑制劑，正在把這一機制帶向更廣泛的靶點功能調控。

RAS長期以來被視為癌癥治療中極具挑戰性的靶點。傳統小分子抑制劑大多依賴于找到可結合口袋，并直接抑制靶點功能。而以Revolution Medicines的daraxonrasib為代表的新一代RAS抑制劑則采用了不同思路：它通過類似于分子膠的機制，誘導RAS蛋白、藥物分子和cyclophilin A伴侶蛋白形成三元復合體，從而阻斷RAS與下游效應蛋白的相互作用。

在今年的ASCO年會上，daraxonrasib的3期臨床試驗結果贏得了全場起立鼓掌。在3期RASolute 302研究中，daraxonrasib用于治療既往接受過治療的轉移性胰腺導管腺癌（PDAC）患者。結果顯示，與標準化療相比，daraxonrasib顯著改善總生存期（OS）和PFS。在意向治療（ITT）人群中，daraxonrasib組的中位OS為13.2個月，化療組為6.7個月。daraxonrasib組的中位PFS為7.2個月，化療組為3.6個月。

該公司基于同樣的分子膠機制開發的RAS G12D抑制劑zoldonrasib，近期在治療轉移性PDAC患者的早期臨床研究中也顯示出令人鼓舞的療效。

其他公司也在利用分子膠作用機制開發RAS抑制劑。今年4月，Erasca公司公布了在研分子膠泛RAS抑制劑ERAS-0015在RAS突變實體瘤患者中的1期劑量遞增試驗初步數據。ERAS-0015在KRAS G12X非小細胞肺癌和KRAS G12X胰腺癌患者中觀察到初步單藥抗腫瘤活性。勁方醫藥（GenFleet Therapeutics）和貝達藥業（Betta Pharmaceuticals）正在開發的泛RAS抑制劑也基于非降解分子膠作用機制，目前已經進入臨床開發階段。

這些RAS研發項目顯示，誘導接近機制的核心并不等同于“降解”。它的本質是通過藥物創造或穩定一個分子復合體，從而改變靶點的功能或穩定性。

大藥企和資本持續加碼，關注點從靶向蛋白降解擴展到廣義誘導接近平臺

誘導接近藥物適應癥和作用機制的拓展，也正在反映到產業合作和資本布局中。2026年第二季度，多項合作和融資事件顯示，產業關注點已經不只局限于經典蛋白降解靶向嵌合體和腫瘤治療領域，而是擴展到DAC、調節誘導接近靶向嵌合體等創新誘導接近平臺，以及誘導接近藥物在其他疾病領域的應用。

6月，羅氏（Roche）與Nurix Therapeutics達成全球合作，共同開發和商業化BTK降解劑bexobrutideg。根據協議，Nurix將獲得7億美元預付款，潛在交易總額最高達23億美元。值得一提的是，雙方聯合開發的bexobrutideg的適應癥不僅覆蓋惡性血液腫瘤，還包括免疫疾病和神經系統疾病，體現了大藥企對蛋白降解劑跨疾病領域開發潛力的重視。

羅氏在同一季度還與C4 Therapeutics圍繞DAC開展了總額超過10億美元的新研發合作。根據協議，C4 Therapeutics將利用其TORPEDO平臺設計降解劑載荷，羅氏負責選擇和設計抗體，并將抗體與降解劑載荷偶聯。DAC將抗體的特異性靶向遞送能力與降解劑載荷的催化作用機制相結合，有望將蛋白降解作用更精準地引導至特定腫瘤細胞或組織中，從而降低對正常組織的影響，并為高活性降解劑載荷提供更具選擇性的遞送方式。這一策略有望在提高療效的同時拓寬治療窗口。

資本市場也在繼續支持探索更廣泛誘導接近機制應用的公司。Flare Therapeutics在6月完成8500萬美元C輪融資，并表示資金將用于推進靶向處于激活狀態的雄激素受體的降解劑FX-111至概念驗證階段，同時推進靶向激活狀態下雄激素受體的調節誘導接近靶向嵌合體項目的臨床前開發。調節誘導接近靶向嵌合體是誘導接近機制在蛋白降解外的另一種應用。這類分子能夠同時結合腫瘤特異性蛋白和另一種對細胞生存至關重要的蛋白，形成穩定的非天然三元復合物，從而破壞必需蛋白的功能，并選擇性殺死癌細胞。

此外，FreeMind Investments和Daewoong Pharmaceutical在5月投資General Proximity。General Proximity試圖系統性尋找能夠調控疾病靶點的效應分子，并利用誘導接近機制將效應分子與靶點蛋白拉近。這些效應分子包括伴侶蛋白、銜接蛋白、運輸蛋白、翻譯后修飾相關蛋白等。將它們與靶點蛋白拉近，可能產生蛋白降解之外的多重生物學作用，包括蛋白激活、重折疊和細胞內重定位。General Proximity已在去年與第一三共（Daiichi Sankyo）達成研發合作；今年再次獲得投資，也顯示了產業界對誘導接近機制更廣泛應用的興趣。

從這些融資和合作可以看出，誘導接近不再只局限于靶向蛋白降解。大藥企和資本關注的是更廣泛的能力組合：如何發現可誘導的新復合體，如何選擇最合適的效應系統，如何實現組織或細胞選擇性，如何將復雜機制轉化為可開發、可生產、可驗證的候選藥物。

一體化平臺助力誘導接近藥物開發

在靶向蛋白降解療法十余年的產業轉化歷程中，藥明康德幾乎全程參與，為合作伙伴提供一體化賦能。在蛋白降解靶向嵌合體剛剛起步時，藥明康德就前瞻性地布局相關能力和技術，搭建了集發現、合成、分析純化和測試等能力于一體的一體化賦能平臺，助力全球合作伙伴高效推進藥物從早期發現到臨床試驗階段。

藥明康德一體化平臺的能力不僅涵蓋靶向蛋白降解分子，還包括分子膠以及多種新興雙功能分子。以分子膠藥物發現為例，早期研發階段中，無偏倚藥物篩選的低命中率始終是一大挑戰。為助力合作伙伴有效應對這一難題，藥明康德采取了“雙軌并進”的策略，構建起一套兼顧廣度與深度的化合物庫體系：一方面，通過多樣化的DNA編碼化合物庫（DEL）大范圍探索新靶點；另一方面，借助聚焦化合物庫精細化研究已知蛋白體系，提升發現效率。

在分子膠藥物的早期發現過程中，藥明康德不僅依賴DNA編碼化合物庫進行篩選，還不斷引入并整合多種先進技術，以助力合作伙伴拓展分子膠藥物的發現能力。其中，親和篩選質譜（ASMS）提供無標記篩選手段。藥明康德構建了一個涵蓋超過37萬個小分子的廣譜化合物庫，通過比較這些分子在單蛋白與雙蛋白條件下的質譜信號差異，精準識別出能夠促進蛋白-蛋白相互作用的潛在分子膠候選物，從而識別出潛在促互作的小分子。

與此同時，公司還部署高通量篩選（HTS）技術。在“一孔一化合物”的自動化運行模式下，結合蛋白結合能力或降解能力等功能性實驗，HTS能迅速鎖定具備生物活性的候選分子，大幅提升篩選效率與準確性。通過將ASMS與HTS等多維篩選工具與DEL平臺深度融合，藥明康德打破了單一篩選方式的限制，讓更多不同類型的靶點進入分子膠研究視野，進一步拓寬了分子膠在多類靶點上的研發空間。

伴隨著新型靶向蛋白降解技術和誘導接近策略的持續涌現，藥明康德緊跟科學前沿，迅速構建相關技術平臺。如今，相關能力已涵蓋蛋白降解靶向嵌合體、調節誘導接近靶向嵌合體、自噬靶向嵌合體、溶酶體靶向嵌合體、去泛素化酶靶向嵌合體、核糖核酸酶靶向嵌合體、磷酸化誘導嵌合小分子以及抗體偶聯降解劑等主要分子類型。展望未來，藥明康德將持續以一體化、端到端的CRDMO賦能平臺，助力全球合作伙伴加速創新藥物的研發生產進程，讓科學突破更快為患者帶來福祉。

Q2 2026 Review of Induced Proximity Drugs

The induced proximity mechanism offers a new way of thinking about drug discovery that differs from the traditional approach of “occupying a target and inhibiting its activity.” By bringing target proteins, E3 ligases, chaperone proteins, antibodies, receptors, or other cellular effector systems into close proximity, drugs can reshape the spatial relationships between molecules and thereby alter the function or fate of disease-related targets. In the second quarter of 2026, the latest progress in the induced proximity field revealed several important trends.

First, the approval of the a “first-in-class” proteolysis targeting chimera, together with positive late-stage clinical results for molecular glue degraders, shows that targeted protein degraders have reached the stage of regulatory validation and are expanding from cancer into broader disease areas such as immunology and inflammation. Second, advances in RAS molecular glue inhibitors and degrader-antibody conjugates (DACs) suggest that induced proximity is no longer limited to “protein degradation,” but is evolving into a broader drug design paradigm. Third, continued collaborations with major pharmaceutical companies and active capital investment show that industry interest in induced proximity medicines is expanding from classic protein degraders to a richer range of induced proximity platforms and complex molecular formats.

To address challenges such as ternary complex formation, target selectivity, delivery, in vivo exposure, pharmacodynamic translation, and CMC development, WuXi AppTec has built an integrated capability system covering multiple molecular types, including proteolysis targeting chimeras, molecular glues, regulated induced proximity targeting chimeras, and degrader-antibody conjugates. Supported by its integrated, end-to-end CRDMO enabling platform, WuXi AppTec provides global partners with systematic support spanning early discovery, screening, synthesis, analytical purification, testing, DMPK, bioanalysis, and subsequent development and manufacturing, helping accelerate more induced proximity medicines toward the clinic and ultimately benefit patients.

The First Proteolysis Targeting Chimera Approved; Protein Degraders Are No Longer Limited to Cancer

In the second quarter of 2026, the induced proximity drug field reached an important milestone. Veppanu (vepdegestrant), jointly developed by Pfizer and Arvinas, was approved by the U.S. FDA for the treatment of adult patients with ESR1-mutated, ER-positive/HER2-negative advanced or metastatic breast cancer. The significance of this approval goes beyond making a new breast cancer therapy available to patients.It demonstrates that the drug design concept of inducing proximity between a target protein and an E3 ligase to achieve targeted protein degradation can be translated into a marketed medicine recognized by regulatory authorities.

At the same time, molecular glue protein degraders continued to generate positive clinical results in hematologic malignancies. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Bristol Myers Squibb announced Phase 3 SUCCESSOR-2 results for its CELMoD agent mezigdomide in combination with carfilzomib and dexamethasone for the treatment of relapsed or refractory multiple myeloma.Compared with the control regimen of carfilzomib and dexamethasone, the mezigdomide combination reduced the risk of disease progression or death by 52%, with median progression-free survival (PFS) of 18.0 months versus 8.3 months, respectively.Another CELMoD agent from the company, iberdomide, is currently under review by the U.S. FDA and may become the first approved CELMoD therapy.

Notably, the application of protein degraders is no longer limited to solid tumors and hematologic malignancies. In April, Kymera Therapeutics announced that the U.S. FDA had granted Fast Track designation to its oral STAT6 degrader KT-621 for the treatment of moderate-to-severe eosinophilic asthma. KT-621 is currently being evaluated in Phase 2b studies in moderate-to-severe eosinophilic asthma and moderate-to-severe atopic dermatitis, with topline results in atopic dermatitis expected by the end of this year. KT-485 (SAR447971), an IRAK4-targeted protein degrader being jointly developed by Kymera and Sanofi, is being evaluated in a Phase 1 clinical trial for patients with hidradenitis suppurativa (HS). Nurix Therapeutics’ Bruton’s tyrosine kinase (BTK) degrader bexobrutideg not only achieved an objective response rate (ORR) of 83% in a Phase 1 clinical trial for chronic lymphocytic leukemia (CLL), but also significantly reduced BTK levels in the skin in early clinical studies, supporting further exploration in inflammatory and immune diseases such as chronic spontaneous urticaria.

Together, these advances show that oncology-focused protein degraders have reached important milestones in late-stage clinical development and regulatory approval.Beyond cancer, protein degraders are also being explored in broader areas such as immune and inflammatory diseases and neurological disorders.For targets such as transcription factors, scaffold proteins, drug-resistant mutant proteins, or proteins with non-enzymatic functions, “degradation” may provide a more comprehensive way to modulate function than “inhibition.”

The Rise of RAS Molecular Glues: Induced Proximity Is No Longer Limited to Protein Degradation

However, induced proximity is not limited to “degrading disease-causing proteins.”Rapidly advancing RAS ternary complex inhibitors are extending this mechanism to broader modulation of target function.

RAS has long been viewed as one of the most challenging targets in cancer therapy. Traditional small-molecule inhibitors largely depend on identifying a druggable binding pocket and directly inhibiting target function. In contrast,next-generation RAS inhibitors such as Revolution Medicines’ daraxonrasib take a different approach: through a molecular glue-like mechanism, they induce the formation of a ternary complex comprising the RAS protein, the drug molecule, and the chaperone protein cyclophilin A, thereby blocking the interaction between RAS and downstream effector proteins.

At this year’s ASCO Annual Meeting, the Phase 3 clinical trial results of daraxonrasib received a standing ovation. In the Phase 3 RASolute 302 study, daraxonrasib was evaluated in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The results showed thatdaraxonrasib significantly improved overall survival (OS) and PFS compared with standard chemotherapy. In the intent-to-treat (ITT) population, median OS was 13.2 months in the daraxonrasib group and 6.7 months in the chemotherapy group.Median PFS was 7.2 months in the daraxonrasib group and 3.6 months in the chemotherapy group.

Zoldonrasib, the company’s RAS G12D inhibitor developed using the same molecular glue mechanism, has also recently shown encouraging efficacy in early clinical studies for patients with metastatic PDAC.

Other companies are also developing RAS inhibitors using molecular glue mechanisms. In April this year, Erasca announced preliminary data from the Phase 1 dose-escalation study of ERAS-0015, an investigational molecular glue pan-RAS inhibitor, in patients with RAS-mutant solid tumors. ERAS-0015 showed preliminary single-agent antitumor activity in patients with KRAS G12X non-small cell lung cancer and KRAS G12X pancreatic cancer. Pan-RAS inhibitors being developed by GenFleet Therapeutics and Betta Pharmaceuticals are also based on a non-degrading molecular glue mechanism and have entered clinical development.

These RAS programs show thatthe core of the induced proximity mechanism is not equivalent to “degradation.” Its essence lies in using a drug to create or stabilize a molecular complex, thereby changing the function or stability of a target.

Major Pharmaceutical Companies and Investors Continue to Invest, Expanding Their Focus from Targeted Protein Degradation to Broader Induced Proximity Platforms

The expansion of induced proximity drugs in both indications and mechanisms is also reflected in industry collaborations and capital deployment. In the second quarter of 2026, multiple collaborations and financing events showed that industry interest is no longer limited to classic proteolysis targeting chimeras and oncology applications, but has expanded to innovative induced proximity platforms such as degrader-antibody conjugates and regulated induced proximity targeting chimeras, as well as applications of induced proximity drugs in other disease areas.

In June, Roche and Nurix Therapeutics entered into a global collaboration to jointly develop and commercialize the BTK degrader bexobrutideg. Under the agreement, Nurix will receive an upfront payment of $700 million, with the total potential deal value of up to $2.3 billion. Notably, the jointly developed bexobrutideg is intended not only for hematologic malignancies, but also for immune diseases and neurological disorders, reflecting major pharmaceutical companies’ recognition of the cross-disease development potential of protein degraders.

In the same quarter, Roche also entered into a new R&D collaboration with C4 Therapeutics focused on DACs, with a total value of more than $1 billion. Under the agreement, C4 Therapeutics will use its TORPEDO platform to design degrader payloads, while Roche will be responsible for selecting and designing antibodies and conjugating them with the degrader payloads.By combining the specific targeted delivery capability of antibodies with the catalytic mechanism of degrader payloads, DACs may direct protein degradation more precisely to specific tumor cells or tissues, thereby reducing effects on normal tissues and providing a more selective delivery approach for highly active degrader payloads.This strategy may help improve efficacy while broadening the therapeutic window.

Investors are also continuing to support companies exploring broader applications of induced proximity mechanisms. In June, Flare Therapeutics completed an $85 million Series C financing. The company said the proceeds will be used to advance FX-111, a degrader targeting the activated androgen receptor, toward proof of concept, while also supporting the preclinical development of its regulated induced proximity targeting chimera program for the activated androgen receptor.Regulated induced proximity targeting chimeras represent another application of induced proximity beyond protein degradation. These molecules can simultaneously bind a tumor-specific protein and another protein essential for cell survival, forming a stable, non-natural ternary complex that disrupts the function of the essential protein and selectively kills cancer cells.

In addition, FreeMind Investments and Daewoong Pharmaceutical invested in General Proximity in May. General Proximity aims to systematically identify effector molecules capable of regulating disease targets and to use induced proximity mechanisms to bring these effector molecules close to target proteins. These effector molecules include chaperone proteins, adaptor proteins, transport proteins, and proteins involved in post-translational modifications. Bringing them into proximity with target proteins may generate multiple biological effects beyond protein degradation, including protein activation, refolding, and intracellular re inducible new complexes localization. General Proximity entered into an R&D collaboration with Daiichi Sankyo last year; its additional investment this year also reflects industry interest in broader applications of induced proximity mechanisms.

Taken together, these financing and collaboration activities show that induced proximity is no longer limited to targeted protein degradation. Major pharmaceutical companies and investors are focusing on a broader set of capabilities: how to discover new inducible complexes, how to select the most appropriate effector systems, how to achieve tissue or cell selectivity, and how to translate complex mechanisms into developable and manufacturable drug candidates.

Integrated Platforms Help Advance the Development of Induced Proximity Drugs

Over more than a decade of targeted protein degradation development in the industry, WuXi AppTec has been deeply involved at every step, providing partners with fully integrated, end-to-end support. Even in the early days of proteolysis targeting chimera research, WuXi AppTec proactively invested in relevant capabilities, establishing a comprehensive platform that spans discovery, synthesis, purification, and testing.

WuXi AppTec’s integrated platform supports not only proteolysis targeting chimera development but also molecular glues and other bifunctional modalities. By uniting cutting-edge screening technologies, tailored library design, and deep scientific expertise, WuXi AppTec offers a fully integrated platform for molecular glue discovery. This approach supports partners across:

? Hit identification and validation

? Mechanistic characterization and degradation profiling

? Lead optimization and SAR development

With the continued emergence of innovative induced proximity technologies, WuXi AppTec remains closely aligned with the scientific frontier and has rapidly built related technology platforms. Today, its capabilities cover major molecular modalities including proteolysis targeting chimeras, regulated induced proximity targeting chimeras, autophagy-targeting chimeras, lysosome-targeting chimeras, deubiquitinase-targeting chimeras, ribonuclease-targeting chimeras, phosphorylation-inducing chimeric small molecules, and degrader-antibody conjugates. Looking ahead, WuXi AppTec will continue leveraging its integrated, end-to-end CRDMO enabling platform to help global partners accelerate the research, development, and manufacturing of innovative medicines—bringing scientific breakthroughs to patients more quickly.

參考資料：

[1] Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting. Retrieved July 2, 2026, from https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-presents-new-preclinical-and-phase-1/

[2] Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration. Retrieved July 2, 2026, from https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-first-participant-dosed-phase-1

[3] Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors. Retrieved July 2, 2026, from https://investors.erasca.com/news-releases/news-release-details/erasca-announces-positive-preliminary-phase-1-dose-escalation

[4] C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs). Retrieved July 2, 2026, from https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-expands-long-term-partnership-roche-through-new

[5] Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology. Retrieved July 2, 2026, from https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-global-collaboration-roche-co

[6] FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in General Proximity. Retrieved July 2, 2026, from https://www.generalproximity.bio/newsposts/freemind-investments-and-daewoong-pharmaceutical-co-invest-in-general-proximity

[7] Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer. Retrieved July 2, 2026, from https://www.flaretx.com/flare-therapeutics-secures-85m-in-insider-led-series-c-financing-and-appoints-anna-protopapas-as-chief-executive-officer/

免責聲明：本文僅作信息交流之目的，文中觀點不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導，請前往正規醫院就診。

版權說明：歡迎個人轉發至朋友圈，謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”，獲取轉載須知。